| |
| Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal |
| Mowatt G, Boachie C, Crowther M, Fraser C, Hernández R, Jia X, Ternent L |
|
|
| |
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mowatt G, Boachie C, Crowther M, Fraser C, Hernández R, Jia X, Ternent L. Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal. Health Technology Assessment 2009; 13 (Suppl 2 Article 9): 63-68 Indexing Status Subject indexing assigned by NLM MeSH Comparative Effectiveness Research; Cost-Benefit Analysiss; Immunosuppressive Agents /economics /therapeutic use; Purpura, Thrombocytopenic, Idiopathic /drug therapy /immunology; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Fc /therapeutic use; Recombinant Fusion Proteins /economics /therapeutic use; Splenectomy; Thrombopoietin /economics /therapeutic use Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32013000710 Date abstract record published 10/10/2013 |
| |
|
|
